Skip to content
Peptidepedia

How to Use Semax: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

Intranasal Spray (Primary Route): Semax is optimized for intranasal delivery, which provides rapid absorption through the nasal mucosa with direct access to the brain via the olfactory and trigeminal nerve pathways. This route bypasses first-pass hepatic metabolism and avoids the peptide degradation that occurs in the gastrointestinal tract. Semax is a particularly good candidate for nasal delivery because of its small molecular weight (seven amino acids), favorable formulation stability at physiological pH, and rapid absorption kinetics — properties that many larger peptides lack, which is why intranasal delivery produces unreliable results for most other peptides.

To administer: clear nasal passages, tilt the head slightly forward, insert the spray tip into one nostril, and depress the pump once while breathing in gently. Alternate nostrils between doses. Avoid blowing the nose for at least 5 minutes after administration to allow absorption.

Subcutaneous Injection (Less Common): Some research protocols and community users administer Semax via subcutaneous injection when using lyophilized powder. This route provides reliable systemic absorption but lacks the direct nasal-to-brain delivery advantage.

Reconstitution (Lyophilized Powder):

  1. Allow the vial to reach room temperature
  2. Add bacteriostatic water slowly along the interior vial wall, do not jet directly onto the powder
  3. Gently swirl until dissolved; do not shake
  4. Common reconstitution ratio: 1:1 (e.g., 10 mg powder + 10 mL bacteriostatic water = 1 mg/mL)
  5. Solution should be clear and colorless; discard if cloudy or discolored

Oral Administration: Not viable. Semax is rapidly degraded by gastrointestinal enzymes, resulting in negligible oral bioavailability.

Reconstitution, Storage & Prep

Semax is available both as a pre-made intranasal solution and as lyophilized powder requiring reconstitution.

Pre-Made Nasal Spray:

  • Store at 2 to 8 degrees C (refrigerator)
  • Protect from light
  • Use within the manufacturer-specified period (typically 30 days after opening)
  • Do not freeze nasal spray formulations

Lyophilized Powder:

  1. Store unreconstituted powder at -20 degrees C for long-term storage; stable at 2 to 8 degrees C for several months
  2. Reconstitute with bacteriostatic water using a 1:1 ratio (e.g., 10 mg + 10 mL = 1 mg/mL)
  3. Add water slowly along the vial wall; swirl gently, do not shake
  4. Reconstituted solution: store at 2 to 8 degrees C and use within 28 days
  5. Discard if solution becomes cloudy, discolored, or contains visible particulates
  6. Protect from light and repeated temperature cycling

For Intranasal Use from Reconstituted Solution: Transfer to a sterile nasal spray bottle that delivers a metered dose. Alternatively, use a micropipette or calibrated dropper for precise volume delivery. Each 0.1 mL of a 1 mg/mL solution delivers 100 mcg.

Frequently Asked Questions

Both are Russian-developed intranasal peptides, but they derive from different parent molecules and target different primary outcomes. Semax is an ACTH(4-7) analog focused on cognitive enhancement, BDNF upregulation, and neuroprotection. Selank is a tuftsin analog that primarily modulates GABA and serotonin for anxiolytic effects. Some practitioners combine them for complementary cognitive and mood support.

The most common intranasal protocol uses 200 to 600 mcg per day, divided into one or two doses. A standard 0.1% nasal spray delivers approximately 300 mcg per pump. Morning administration is preferred due to dopaminergic stimulation. Clinical use in Russia employs 10 to 30 day courses, with the 1% solution reserved for acute neurological conditions under medical supervision.

Semax is generally well-tolerated. The most commonly reported side effects are mild nasal irritation, occasional headache, and sleep disturbance if administered too late in the day. Less common reports include transient anxiety, nausea, and minor blood pressure fluctuations. No serious adverse events have been reported in published clinical or preclinical research.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dergunova LV, Filippenkov IB, Stavchansky VV, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020;11(6):681.
  2. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. BMC Neurosci. 2014;15:63.
  3. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35.
  4. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
  5. Kaplan AY, Kochetova AG, Nezavibathko VN, Rzhevskii DA, Roshchina IF, Ashmarin IP. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(2):306-310.
  6. Gusev EI, Skvortsova VI, Chukanova EI. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68.
  7. Gavrilova SA, Golubev AI, Lipina TV, et al. Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(5):15-19.
  8. Ioseliani TK, Kozaev GG, Poletaeva II, Elizarova IP. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestn Oftalmol. 2001;117(4):5-8.
  9. Filippenkov IB, Remizova JA, Denisova AE, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2024;44(1):71.
  10. Myasoedov NF, Andreyeva LA, Grigorjeva ME, et al. Development of peptide biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716.
  11. Stavchansky VV, Dergunova LV, Filippenkov IB, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021;22(12):6179.
←Read the full Semax guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”